We initially identified promising programs using two publications (detailed below). We then investigated each program in detail. We consider a program to be a "priority" if it is:
- "Low burden-of-proof." Some medical treatments have very strong evidence behind their basic effectiveness (i.e., connecting successful adherence to a drug regime with recovery from tuberculosis). Rather than demonstrating long-term impact on mortality and other health outcomes, a charity may be able to make a substantial case for its impact simply by demonstrating successful delivery of proven treatments. See the "Conditions under which program is effective" column; programs requiring behavior change are generally (with one exception, noted below) not considered to lower the burden of proof enough to fall in this category.
- Reasonably cost-effective: in the range of $100 per disability-adjusted life-year (DALY) averted, $50 per life-year significantly changed, or $1000 per life significantly changed. (Specifics of the type of life change associated with each intervention are included in the table.) More on the DALY metric here; more on our use of cost-effectiveness estimates here.
All of the programs we have identified as priority program are in the area of health. For more information on the evidence for other types of programs, see our overviews of developing-world education and economic empowerment.
Priority programs
| Disease |
Program |
Writeup |
Conditions under which program is effective |
Cost per DALY |
Cost-effectiveness in life/life-year terms |
| Vaccine-preventable diseases |
Expanding immunization coverage |
Click here |
Functional vaccines administered to at-risk populations |
$2-$20 |
$169-$1,754 per death averted, depending on region |
| Malaria |
Distribution of insecticide-treated nets (ITNs) |
Click here |
ITNs consistently used by at-risk people (infants and pregnant women) |
$5-$31 |
$180-$1100 prevents one death and 320 less severe malaria episodes |
| Malaria |
Drug treatment including artemisinin combination therapy (ACT) |
Click here |
Appropriate drug regimen adhered to by patients |
In the range of $150 |
Range of $5450 per death (and 320 less severe malaria episodes) averted |
| Tuberculosis |
Tuberculosis case finding and treatment |
Click here |
Appropriate drug regimen adhered to by patients |
$5-$50 |
$150-$750 per death averted |
| Lymphatic filariasis |
Mass drug administraiton to control lymphatic filariasis |
Click here |
Appropriate drugs administered to at-risk populations |
$4.40-$29 |
$100 prevents 15-85 total years of lymphedema (swollen limbs) and 25-165 total years of hydrocele (swollen scrotum) |
| River blindness (onchocerciasis) |
Mass drug administraiton to control river blindness |
Click here |
Appropriate drugs administered to at-risk populations |
$7-$40 |
$100 prevents 2.5-14 years of blindness; 3.5-20 years of irritating skin disease; AND 3-17 years of impaired vision |
| Schistosomiasis and soil-transmitted helminths |
Combination deworming program (mass drug administration) |
Click here |
Appropriate drugs administered to at-risk populations |
$3.36-$19 |
$5 per additional year of school attendance for students |
| Surgery-correctable conditions |
Surgeries (missions and support of local surgeons) |
Click here |
Surgeries appropriately executed |
$87-$300 |
$30-$1400 per surgery performed; impact of surgeries varies widely |
| HIV/AIDS |
Prevention of mother-to-child transmission (PMTCT) |
Click here |
Appropriate drugs administered to at-risk populations |
$6-$12 |
$150-$300 HIV infection averted |
| Malnutrition |
Vitamin supplementation/fortification |
Writeups forthcoming |
Forthcoming |
Forthcoming |
Forthcoming |
Non-priority programs we've investigated
| Disease |
Program |
Writeup |
Conditions under which program is effective |
Cost per DALY |
Cost-effectiveness in life/life-year terms |
| Diarrheal disease |
Water infrastructure programs |
Click here |
Even clean water may not lead to significant health impact. |
159 |
~$5000 averts a death and ~2100 less severe diarrhea episodes |
| HIV/AIDS |
Antiretroviral therapy |
Click here |
Appropriate drug regimen adhered to by patients |
$350-$1,494 |
$129.50-$552.78 per year spent on ART, which partially but not fully alleviates AIDS symptoms |
| HIV/AIDS |
Condom promotion and distribution |
Click here |
Condoms used consistently by at-risk individuals |
$52-$112 |
$1040-$2240 per HIV infection averted |
| Trachoma |
SAFE Strategy to control trachoma |
Click here |
Surgeries appropriately executed; appropriate antibiotics administered to population |
Surgeries: $4-82. Antibiotics: ~$4,000. Other components: unknown. |
Surgeries: $100 prevents 1-30 years of blindness and 1-30 years of low vision. Other components: highly costly or unknown. |
| Polio / guinea worm |
Disease eradication programs |
Click here |
Vary by disease |
Depends heavily on whether eradication achieved |
Depends heavily on whether eradication achieved |
| Guinea worm (dracunculiasis) |
Safe water, health education, case management and close surveillance |
Click here |
Past successes in high prevalance conditions |
Future cost-effectiveness could be very different from past cost-effectiveness |
Future cost-effectiveness could be very different from past cost-effectiveness |
| Unwanted pregnancies |
Family planning services |
Writeups forthcoming |
Forthcoming |
Forthcoming |
Forthcoming |
How we identified programs for investigation
We initially sought to identify promising programs by reviewing two sources:
- The Copenhagen Consensus, the only case we have seen of an independent panel of experts attempting to identify the most promising philanthropic investments (discussed more here)
- Millions Saved, the best collection we have found of large-scale, well-documented past successes in international aid (discussed more here)
If a program was both featured in one of these two publications and similar to a program focused on by one or more of the charities we reviewed, we generally conducted further investigation into the program. Details on which programs are featured in these two publications, which similar programs are focused on by the charities we've reviewed, and which programs we investigated are available in here.
Over time, our criteria have shifted and we now focus on identifying programs that "lower the burden of proof" as well as being reasonably cost-effective.